The global market for Immunotherapy for Neuroblastoma was estimated to be worth US$ 45 million in 2023 and is forecast to a readjusted size of US$ 63 million by 2030 with a CAGR of 4.6% during the forecast period 2024-2030

Immunotherapy for Neuroblastoma - Market

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

North American market for Immunotherapy for Neuroblastoma was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Immunotherapy for Neuroblastoma was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Immunotherapy for Neuroblastoma was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Immunotherapy for Neuroblastoma include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Immunotherapy for Neuroblastoma, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Immunotherapy for Neuroblastoma by region & country, by Type, and by Application.

The Immunotherapy for Neuroblastoma market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immunotherapy for Neuroblastoma.

Market Segmentation

Scope of Immunotherapy for Neuroblastoma - Market Report

Report Metric	Details
Report Name	Immunotherapy for Neuroblastoma - Market
Forecasted market size in 2030	US$ 63 million
CAGR	4.6%
Forecasted years	2024 - 2030
Segment by Type:	Dinutuximab Naxitamab Other
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Immunotherapy for Neuroblastoma manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Immunotherapy for Neuroblastoma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Immunotherapy for Neuroblastoma in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Immunotherapy for Neuroblastoma - Market size in 2030?

Ans: The Immunotherapy for Neuroblastoma - Market size in 2030 will be US$ 63 million.

Who are the main players in the Immunotherapy for Neuroblastoma - Market report?

Ans: The main players in the Immunotherapy for Neuroblastoma - Market are United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals

What are the Application segmentation covered in the Immunotherapy for Neuroblastoma - Market report?

Ans: The Applications covered in the Immunotherapy for Neuroblastoma - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Immunotherapy for Neuroblastoma - Market report?

Ans: The Types covered in the Immunotherapy for Neuroblastoma - Market report are Dinutuximab, Naxitamab, Other

1 Market Overview

1.1 Immunotherapy for Neuroblastoma Product Introduction

1.2 Global Immunotherapy for Neuroblastoma Market Size Forecast

1.3 Immunotherapy for Neuroblastoma Market Trends & Drivers

1.3.1 Immunotherapy for Neuroblastoma Industry Trends

1.3.2 Immunotherapy for Neuroblastoma Market Drivers & Opportunity

1.3.3 Immunotherapy for Neuroblastoma Market Challenges

1.3.4 Immunotherapy for Neuroblastoma Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Immunotherapy for Neuroblastoma Players Revenue Ranking (2023)

2.2 Global Immunotherapy for Neuroblastoma Revenue by Company (2019-2024)

2.3 Key Companies Immunotherapy for Neuroblastoma Manufacturing Base Distribution and Headquarters

2.4 Key Companies Immunotherapy for Neuroblastoma Product Offered

2.5 Key Companies Time to Begin Mass Production of Immunotherapy for Neuroblastoma

2.6 Immunotherapy for Neuroblastoma Market Competitive Analysis

2.6.1 Immunotherapy for Neuroblastoma Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Immunotherapy for Neuroblastoma Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy for Neuroblastoma as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Dinutuximab

3.1.2 Naxitamab

3.1.3 Other

3.2 Global Immunotherapy for Neuroblastoma Sales Value by Type

3.2.1 Global Immunotherapy for Neuroblastoma Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Immunotherapy for Neuroblastoma Sales Value, by Type (2019-2030)

3.2.3 Global Immunotherapy for Neuroblastoma Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Other

4.2 Global Immunotherapy for Neuroblastoma Sales Value by Application

4.2.1 Global Immunotherapy for Neuroblastoma Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Immunotherapy for Neuroblastoma Sales Value, by Application (2019-2030)

4.2.3 Global Immunotherapy for Neuroblastoma Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Immunotherapy for Neuroblastoma Sales Value by Region

5.1.1 Global Immunotherapy for Neuroblastoma Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Immunotherapy for Neuroblastoma Sales Value by Region (2019-2024)

5.1.3 Global Immunotherapy for Neuroblastoma Sales Value by Region (2025-2030)

5.1.4 Global Immunotherapy for Neuroblastoma Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Immunotherapy for Neuroblastoma Sales Value, 2019-2030

5.2.2 North America Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Immunotherapy for Neuroblastoma Sales Value, 2019-2030

5.3.2 Europe Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Immunotherapy for Neuroblastoma Sales Value, 2019-2030

5.4.2 Asia Pacific Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Immunotherapy for Neuroblastoma Sales Value, 2019-2030

5.5.2 South America Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Immunotherapy for Neuroblastoma Sales Value, 2019-2030

5.6.2 Middle East & Africa Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Immunotherapy for Neuroblastoma Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Immunotherapy for Neuroblastoma Sales Value

6.3 United States

6.3.1 United States Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.3.2 United States Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.4.2 Europe Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.5.2 China Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.5.3 China Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.6.2 Japan Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.7.2 South Korea Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.8.2 Southeast Asia Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Immunotherapy for Neuroblastoma Sales Value, 2019-2030

6.9.2 India Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

6.9.3 India Immunotherapy for Neuroblastoma Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 United Therapeutics

7.1.1 United Therapeutics Profile

7.1.2 United Therapeutics Main Business

7.1.3 United Therapeutics Immunotherapy for Neuroblastoma Products, Services and Solutions

7.1.4 United Therapeutics Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.1.5 United Therapeutics Recent Developments

7.2 Y-mAbs Therapeutics

7.2.1 Y-mAbs Therapeutics Profile

7.2.2 Y-mAbs Therapeutics Main Business

7.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Products, Services and Solutions

7.2.4 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.2.5 Y-mAbs Therapeutics Recent Developments

7.3 EUSA Pharma

7.3.1 EUSA Pharma Profile

7.3.2 EUSA Pharma Main Business

7.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Products, Services and Solutions

7.3.4 EUSA Pharma Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.3.5 ANI Pharmaceuticals Recent Developments

7.4 ANI Pharmaceuticals

7.4.1 ANI Pharmaceuticals Profile

7.4.2 ANI Pharmaceuticals Main Business

7.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

7.4.4 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.4.5 ANI Pharmaceuticals Recent Developments

7.5 Baxter Healthcare

7.5.1 Baxter Healthcare Profile

7.5.2 Baxter Healthcare Main Business

7.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Products, Services and Solutions

7.5.4 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.5.5 Baxter Healthcare Recent Developments

7.6 Ingenus Pharmaceuticals

7.6.1 Ingenus Pharmaceuticals Profile

7.6.2 Ingenus Pharmaceuticals Main Business

7.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

7.6.4 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.6.5 Ingenus Pharmaceuticals Recent Developments

7.7 Pfizer

7.7.1 Pfizer Profile

7.7.2 Pfizer Main Business

7.7.3 Pfizer Immunotherapy for Neuroblastoma Products, Services and Solutions

7.7.4 Pfizer Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.7.5 Pfizer Recent Developments

7.8 Hikma Pharmaceuticals

7.8.1 Hikma Pharmaceuticals Profile

7.8.2 Hikma Pharmaceuticals Main Business

7.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

7.8.4 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.8.5 Hikma Pharmaceuticals Recent Developments

7.9 Teva Pharmaceuticals

7.9.1 Teva Pharmaceuticals Profile

7.9.2 Teva Pharmaceuticals Main Business

7.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

7.9.4 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (US$ Million) & (2019-2024)

7.9.5 Teva Pharmaceuticals Recent Developments

8 Industry Chain Analysis

8.1 Immunotherapy for Neuroblastoma Industrial Chain

8.2 Immunotherapy for Neuroblastoma Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Immunotherapy for Neuroblastoma Sales Model

8.5.2 Sales Channel

8.5.3 Immunotherapy for Neuroblastoma Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Ingenus Pharmaceuticals

Pfizer Inc

Hikma Pharmaceuticals

Teva Pharmaceuticals

List of Tables

Table 1. Immunotherapy for Neuroblastoma Market Trends

Table 2. Immunotherapy for Neuroblastoma Market Drivers & Opportunity

Table 3. Immunotherapy for Neuroblastoma Market Challenges

Table 4. Immunotherapy for Neuroblastoma Market Restraints

Table 5. Global Immunotherapy for Neuroblastoma Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Immunotherapy for Neuroblastoma Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Immunotherapy for Neuroblastoma Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Immunotherapy for Neuroblastoma Product Type

Table 9. Key Companies Time to Begin Mass Production of Immunotherapy for Neuroblastoma

Table 10. Global Immunotherapy for Neuroblastoma Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immunotherapy for Neuroblastoma as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Immunotherapy for Neuroblastoma Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Immunotherapy for Neuroblastoma Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Immunotherapy for Neuroblastoma Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Immunotherapy for Neuroblastoma Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Immunotherapy for Neuroblastoma Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Immunotherapy for Neuroblastoma Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Immunotherapy for Neuroblastoma Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Immunotherapy for Neuroblastoma Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Immunotherapy for Neuroblastoma Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Immunotherapy for Neuroblastoma Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Immunotherapy for Neuroblastoma Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Immunotherapy for Neuroblastoma Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Immunotherapy for Neuroblastoma Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Immunotherapy for Neuroblastoma Sales Value by Region (2019-2024) & (%)

Table 27. Global Immunotherapy for Neuroblastoma Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Immunotherapy for Neuroblastoma Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Immunotherapy for Neuroblastoma Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Immunotherapy for Neuroblastoma Sales Value, (2025-2030) & (US$ Million)

Table 31. United Therapeutics Basic Information List

Table 32. United Therapeutics Description and Business Overview

Table 33. United Therapeutics Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 34. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of United Therapeutics (2019-2024)

Table 35. United Therapeutics Recent Developments

Table 36. Y-mAbs Therapeutics Basic Information List

Table 37. Y-mAbs Therapeutics Description and Business Overview

Table 38. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 39. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of Y-mAbs Therapeutics (2019-2024)

Table 40. Y-mAbs Therapeutics Recent Developments

Table 41. EUSA Pharma Basic Information List

Table 42. EUSA Pharma Description and Business Overview

Table 43. EUSA Pharma Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 44. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of EUSA Pharma (2019-2024)

Table 45. EUSA Pharma Recent Developments

Table 46. ANI Pharmaceuticals Basic Information List

Table 47. ANI Pharmaceuticals Description and Business Overview

Table 48. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 49. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of ANI Pharmaceuticals (2019-2024)

Table 50. ANI Pharmaceuticals Recent Developments

Table 51. Baxter Healthcare Basic Information List

Table 52. Baxter Healthcare Description and Business Overview

Table 53. Baxter Healthcare Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 54. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of Baxter Healthcare (2019-2024)

Table 55. Baxter Healthcare Recent Developments

Table 56. Ingenus Pharmaceuticals Basic Information List

Table 57. Ingenus Pharmaceuticals Description and Business Overview

Table 58. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 59. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of Ingenus Pharmaceuticals (2019-2024)

Table 60. Ingenus Pharmaceuticals Recent Developments

Table 61. Pfizer Basic Information List

Table 62. Pfizer Description and Business Overview

Table 63. Pfizer Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 64. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of Pfizer (2019-2024)

Table 65. Pfizer Recent Developments

Table 66. Hikma Pharmaceuticals Basic Information List

Table 67. Hikma Pharmaceuticals Description and Business Overview

Table 68. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 69. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of Hikma Pharmaceuticals (2019-2024)

Table 70. Hikma Pharmaceuticals Recent Developments

Table 71. Teva Pharmaceuticals Basic Information List

Table 72. Teva Pharmaceuticals Description and Business Overview

Table 73. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Products, Services and Solutions

Table 74. Revenue (US$ Million) in Immunotherapy for Neuroblastoma Business of Teva Pharmaceuticals (2019-2024)

Table 75. Teva Pharmaceuticals Recent Developments

Table 76. Key Raw Materials Lists

Table 77. Raw Materials Key Suppliers Lists

Table 78. Immunotherapy for Neuroblastoma Downstream Customers

Table 79. Immunotherapy for Neuroblastoma Distributors List

Table 80. Research Programs/Design for This Report

Table 81. Key Data Information from Secondary Sources

Table 82. Key Data Information from Primary Sources

Table 83. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Immunotherapy for Neuroblastoma Product Picture

Figure 2. Global Immunotherapy for Neuroblastoma Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Immunotherapy for Neuroblastoma Sales Value (2019-2030) & (US$ Million)

Figure 4. Immunotherapy for Neuroblastoma Report Years Considered

Figure 5. Global Immunotherapy for Neuroblastoma Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Immunotherapy for Neuroblastoma Revenue in 2023

Figure 7. Immunotherapy for Neuroblastoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Dinutuximab Picture

Figure 9. Naxitamab Picture

Figure 10. Other Picture

Figure 11. Global Immunotherapy for Neuroblastoma Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Immunotherapy for Neuroblastoma Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Hospital

Figure 14. Product Picture of Clinic

Figure 15. Product Picture of Other

Figure 16. Global Immunotherapy for Neuroblastoma Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Immunotherapy for Neuroblastoma Sales Value Market Share by Application, 2023 & 2030

Figure 18. North America Immunotherapy for Neuroblastoma Sales Value (2019-2030) & (US$ Million)

Figure 19. North America Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

Figure 20. Europe Immunotherapy for Neuroblastoma Sales Value (2019-2030) & (US$ Million)

Figure 21. Europe Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

Figure 22. Asia Pacific Immunotherapy for Neuroblastoma Sales Value (2019-2030) & (US$ Million)

Figure 23. Asia Pacific Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

Figure 24. South America Immunotherapy for Neuroblastoma Sales Value (2019-2030) & (US$ Million)

Figure 25. South America Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

Figure 26. Middle East & Africa Immunotherapy for Neuroblastoma Sales Value (2019-2030) & (US$ Million)

Figure 27. Middle East & Africa Immunotherapy for Neuroblastoma Sales Value by Country (%), 2023 VS 2030

Figure 28. Key Countries/Regions Immunotherapy for Neuroblastoma Sales Value (%), (2019-2030)

Figure 29. United States Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 30. United States Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 31. United States Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 32. Europe Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 33. Europe Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 34. Europe Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 35. China Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 36. China Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 37. China Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 38. Japan Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 39. Japan Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 40. Japan Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 41. South Korea Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 42. South Korea Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 43. South Korea Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 44. Southeast Asia Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 46. Southeast Asia Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 47. India Immunotherapy for Neuroblastoma Sales Value, (2019-2030) & (US$ Million)

Figure 48. India Immunotherapy for Neuroblastoma Sales Value by Type (%), 2023 VS 2030

Figure 49. India Immunotherapy for Neuroblastoma Sales Value by Application (%), 2023 VS 2030

Figure 50. Immunotherapy for Neuroblastoma Industrial Chain

Figure 51. Immunotherapy for Neuroblastoma Manufacturing Cost Structure

Figure 52. Channels of Distribution (Direct Sales, and Distribution)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-39R14639

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Cancer Early Detection and Diagnosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37I14671

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global One-Stop Radiotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-33G18542

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Immunotherapy for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-1A14903

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Immunotherapy for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: December 2024

Report Code: QYRE-Auto-1A14903

Immunotherapy for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Immunotherapy for Neuroblastoma - Market Size

Immunotherapy for Neuroblastoma - Market

Report Scope

Scope of Immunotherapy for Neuroblastoma - Market Report

Chapter Outline

FAQ for this report

What is the Immunotherapy for Neuroblastoma - Market size in 2030?

Who are the main players in the Immunotherapy for Neuroblastoma - Market report?

What are the Application segmentation covered in the Immunotherapy for Neuroblastoma - Market report?

What are the Type segmentation covered in the Immunotherapy for Neuroblastoma - Market report?

FEATURED COMPANIES

RELATED REPORTS